Beck O A, Lehmann H U, Hochrein H
Dtsch Med Wochenschr. 1978 Jun 30;103(26):1068-72. doi: 10.1055/s-0028-1104816.
60 patients with chronic atrial fibrillation and flutter were randomly allotted to two groups and treated alternately with two different therapy regimes. 30 patients (group I) received lidoflazine in increasing dosage up to 480 mg/24 h and in cases where there was no conversion to sinus rhythm propafenon in a maximal daily dosage of 1800 mg orally. The duration of treatment was limited to 4 days for each substance. 30 patients (group II) were treated in the reverse order, i.e. propafenon and in cases of ineffectiveness with lidoflazine. Atrial fibrillation could be overcome in 21 patients in group I and in 23 patients in group II. The combined success rate in both groups was 73%. The conversion rates for the individual substances were 41% for propafenon (17 out of 41 patients) and 59% for lidoflazine (27 out of 46 patients). The difference was not statistically significant. Successive use of both substances leads to an increased conversion rate. Dangers arising from therapy are a conduction inhibitory action and depression of sinus node function as far as propafenol is concerned and the risk of ventricular ectopy and tachyarrhythmia in lidoflazine.
60例慢性心房颤动和心房扑动患者被随机分为两组，交替接受两种不同的治疗方案。30例患者（I组）先接受利多氟嗪治疗，剂量逐渐增加至480mg/24h，若未转为窦性心律，则口服最大日剂量为1800mg的普罗帕酮。每种药物的治疗时间限制为4天。30例患者（II组）接受相反顺序的治疗，即先使用普罗帕酮，无效时再使用利多氟嗪。I组有21例患者、II组有23例患者的心房颤动得以纠正。两组的总成功率为73%。普罗帕酮的转复率为41%（41例患者中有17例），利多氟嗪的转复率为59%（46例患者中有27例）。差异无统计学意义。两种药物相继使用可提高转复率。治疗带来的风险方面，就普罗帕酮而言，有传导抑制作用和窦房结功能抑制，就利多氟嗪而言，有室性早搏和快速性心律失常的风险。
